Adaptimmune Therapeutics PLC — Director's Dealing 2018

Jan 17, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2018-01-12

Reporting Person: Binder-Scholl Gwendolyn Knowlton (Chief Technology Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-12	Option to purchase Ordinary Shares	$1.30	A	429984	Acquired	2028-01-12	Ordinary Shares (429984)	Direct
2018-01-12	Option to purchase Ordinary Shares	$0.0014	A	96036	Acquired		Ordinary Shares (96036)	Direct

Footnotes

F1: The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 107,496 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 8,958 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 24,009 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 24,009 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.